PubRank

V E Prise

Author PubWeight™ 21.32‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997 2.96
2 Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999 1.79
3 Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001 1.75
4 Tumour vascular disrupting agents: combating treatment resistance. Br J Radiol 2008 1.19
5 Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res 1997 0.94
6 Characterisation of tumour blood flow using a 'tissue-isolated' preparation. Br J Cancer 1994 0.93
7 The influence of vasoactive agents on the perfusion of tumours growing in three sites in the mouse. Int J Radiat Biol 1991 0.88
8 The influence of nitric oxide on tumour vascular tone. Acta Oncol 1995 0.87
9 Resistance to flow through tissue-isolated transplanted rat tumours located in two different sites. Br J Cancer 1993 0.85
10 Nitric oxide in biological fluids: analysis of nitrite and nitrate by high-performance ion chromatography. J Chromatogr A 1995 0.85
11 The comparative effects of the NOS inhibitor, Nomega-nitro-L-arginine, and the haemoxygenase inhibitor, zinc protoporphyrin IX, on tumour blood flow. Int J Radiat Oncol Biol Phys 1998 0.85
12 Reduced capacity of tumour blood vessels to produce endothelium-derived relaxing factor: significance for blood flow modification. Br J Cancer 1996 0.80
13 Spatial heterogeneity of tumour blood flow modification induced by angiotensin II: relationship to receptor distribution. Int J Cancer 1996 0.80
14 The endothelin B (ETB) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification. Br J Cancer 2005 0.78
15 Effect of endothelin-1 and sarafotoxin S6c on blood flow in a rat tumor. J Cardiovasc Pharmacol 1995 0.78
16 Tumour blood flow modification by endothelin-related peptides in the rat HSN fibrosarcoma. Br J Cancer Suppl 1996 0.78
17 Vascular response of tumour and normal tissues to endothelin-1 following antagonism of ET(A) and ET(B) receptors in anaesthetised rats. Int J Cancer 1997 0.77
18 The effects of pentoxifylline on the relative perfusion of tumours growing in three sites in the mouse. Br J Cancer 1993 0.77
19 The modification of blood flow in tumours and their supplying arteries by nicotinamide. Acta Oncol 1995 0.76
20 A comparative study of tumour blood flow modification in two rat tumour systems using endothelin-1 and angiotensin II: influence of tumour size on angiotensin II response. Int J Cancer 1996 0.76
21 Modification of blood flow in the HSN tumour and normal tissues of the rat by the endothelin ET(B) receptor agonist, IRL 1620. Int J Cancer 1999 0.76
22 Relative perfusion of tumours in two sites for up to 6 hours after the induction of anaemia. Adv Exp Med Biol 1994 0.75
23 Characterisation of the microcirculation of tumours where the blood supply originates from a single artery and vein. Adv Exp Med Biol 1994 0.75